Multiple cranial nerve deficits as preceding symptoms of systemic non-Hodgkin's lymphoma
Multiple cranial nerve deficit is a common neurological manifestation. It is usually presented in schwannoma and meningioma patients but rarely in lymphoma. 1 Non-Hodgkin's lymphoma accounts for 90% of lymphomas, and its clinical manifestations differ with diverse primary sites.
2 Approximately 5%-10% of systemic non-Hodgkin's lymphoma is characteristic of central nervous system invasion, such as secondary central nervous system lymphoma. 3 Multiple cranial nerve deficits are rarely the primary manifestation of non-Hodgkin's lymphoma. In this study, we aimed to prove that multiple cranial nerve deficit can be onset symptom of non-Hodgkin's lymphoma. In addition, neurologists should pay more attention to the diagnosis of lymphoma in the patients with cranial nerve deficit.
We retrospectively analyzed the clinical, radiological, patho- The study protocol has been approved by local committee on human research, and we got informed consent of the patients.
The average age of the patients was 46 years old (range from 24 to 67),with 2 males and three females. The patients' clinical, radiological, and cerebrospinal fluid features are shown in Table 1 .
Symptoms of multiple cranial nerve deficits of the patients involved Cranial nerves involvement could be related to many causes such as CNS inflammation, brain tumor, cerebrovascular disease, craniocerebral trauma, infection, and diabetic multiple cranial nerve deficits.
And it is a rare onset symptom in lymphoma patients. In these patients, cranial nerves involvement can be easily misdiagnosed as diseases as mentioned above. CNS infiltration is a rare but highly lethal complication of malignant lymphoma, with a median survival of only 4-5 months. 7 The occurrence of CNS invasion in DLBCL is rather rare. Ferreri et al found that CNS invasion was present in 2-5% of DLBCL patients after diagnosis or during progression and relapse.
8
The patients with CNS invasion prior to lymphoma diagnosis had significantly longer survival time. 9 Proved standard therapies on SCNSL are limited, in patients with SCNSL, longer survival has been observed, particularly when high-dose methotrexate (HDMTX)-based chemotherapy was administered. 10 Only Case 1 who had a longer survival time underwent chemotherapy and HDMTX after diagnosis.
In conclusion, it is important for a neurologist to pay attention to the diagnosis of lymphoma when patients manifest with multiple cranial nerve deficits as primary or main clinical symptoms. It requires the integration of knowledge from neurology and hematology. In general, cytology of the CSF is important for diagnosis, and PET-CT examination can be used to clarify the degree of involvement of the entire body, while the biopsy of pathological tissues is the gold standard for diagnosis.
